Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Growth Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Vanguard Growth Index Fund ETF trades at $86.96. Which is the better fit depends on your goals.
| AMLX | VUG | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Sector/Thematic |
52-Week High | $18.70 | $90.29 |
52-Week Low | $7.64 | $70.00 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VUG trades at $87.4, up 0.48% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights its strong long-term growth focus, with 70% tech exposure and low expense ratio of 0.03%. The ETF executed a 1:6 stock split in April 2026 and has a dividend scheduled for June 2026.
Outlook remains positive due to tech-driven growth and cost efficiency, but risks include high tech concentration and market volatility. Analyst sentiment is favorable for long-term holdings, though short-term indicators suggest caution near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
